Abstract
A large number of clinical trials are underway to assess the therapeutic potential of mesenchymal stromal cells. This is based on preclinical observations that point to the probable efficacy of these cells. Very little is known however about the homing mechanisms of these cells to sites of injury and inflammation. This is important if one is to enhance this process to improve the therapeutic outcome. We have addressed this issue by highlighting what is known and through an analogy with leukocyte homing, and have identified possible areas of future research.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.